Immunohistochemistry (IHC) and immunoblot analysis of tumor lysates confirmed elevated PIM3 levels and more effective inhibition of pPRAS40, pS6, p4EBP1, pBAD by the combination treatment in the G-R3 X1.2 tumors, while ipatasertib alone was effective in the Par X1.6 tumors (Supplementary Fig. 12a–c). Here, PIM3 is linked to neoplasm.